Patents by Inventor Max Allen Schwarzer

Max Allen Schwarzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR IGM ANTIBODIES AND USES THEREOF
    Publication number: 20230203173
    Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
    Type: Application
    Filed: November 14, 2022
    Publication date: June 29, 2023
    Inventors: Beatrice WANG, Max Allen SCHWARZER, Bruce Alan KEYT, Ramesh BALIGA
  • Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules
    Patent number: 11578131
    Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: February 14, 2023
    Assignee: IGM Biosciences, Inc.
    Inventors: Beatrice Wang, Max Allen Schwarzer, Bruce Alan Keyt, Ramesh Baliga
  • TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF
    Publication number: 20210047419
    Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
    Type: Application
    Filed: April 28, 2020
    Publication date: February 18, 2021
    Inventors: Beatrice WANG, Max Allen SCHWARZER, Bruce Alan KEYT, Ramesh BALIGA
  • Tumor necrosis factor (TNF) superfamily receptor IgM antibodies and uses thereof
    Patent number: 9938347
    Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: April 10, 2018
    Assignee: IGM BIOSCIENCES A/S
    Inventors: Beatrice Tien-Yi Wang, Max Allen Schwarzer, Bruce Alan Keyt, Ramesh Baliga
  • TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF
    Publication number: 20170320955
    Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
    Type: Application
    Filed: June 30, 2017
    Publication date: November 9, 2017
    Inventors: Beatrice Tien-Yi Wang, Max Allen Schwarzer, Bruce Alan Keyt, Ramesh Baliga